NEUROONE MEDICAL TECHNOLOGIES Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NEUROONE MEDICAL TECHNOLOGIES Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $9.10M | Dec 17, 2025 |
| FY2025 | Sep 30, 2024 | $3.45M | Dec 17, 2025 |
| FY2024 | Sep 30, 2023 | $1.95M | Dec 17, 2024 |
| FY2023 | Sep 30, 2022 | $171.2K | Dec 15, 2023 |
| FY2022 | Sep 30, 2021 | $178.1K | Dec 22, 2022 |
| FY2012 | Dec 31, 2012 | $921 | Apr 11, 2013 |
| FY2012 | Dec 31, 2011 | $5.4K | Apr 11, 2013 |
| FY2011 | Dec 31, 2010 | $1.2K | Mar 28, 2012 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $0 | Apr 17, 2017 |
| FY2016 | Dec 31, 2015 | $0 | Apr 17, 2017 |
| FY2015 | Dec 31, 2014 | $773 | Apr 14, 2016 |
| FY2014 | Dec 31, 2013 | $1.2K | Apr 15, 2015 |
| FY2013 | Dec 31, 2012 | $921 | Apr 24, 2014 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $5.14M | Dec 17, 2025 |
| FY2025 | Sep 30, 2024 | $1.08M | Dec 17, 2025 |
| FY2024 | Sep 30, 2023 | $456.5K | Dec 17, 2024 |
| FY2023 | Sep 30, 2022 | ($70.8K) | Dec 15, 2023 |
| FY2022 | Sep 30, 2021 | ($97.7K) | Dec 22, 2022 |
| FY2013 | Dec 31, 2013 | $1.2K | Apr 24, 2014 |
| FY2013 | Dec 31, 2012 | $921 | Apr 24, 2014 |
| FY2012 | Dec 31, 2011 | $3.3K | Apr 11, 2013 |
| FY2011 | Dec 31, 2010 | $1.2K | Mar 28, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($3.61M) | Dec 17, 2025 |
| FY2025 | Sep 30, 2024 | ($12.32M) | Dec 17, 2025 |
| FY2024 | Sep 30, 2023 | ($11.86M) | Dec 17, 2024 |
| FY2023 | Sep 30, 2022 | ($10.00M) | Dec 15, 2023 |
| FY2022 | Sep 30, 2021 | ($9.95M) | Dec 22, 2022 |
| FY2021 | Sep 30, 2020 | ($13.64M) | May 31, 2022 |
| FY2020 | Sep 30, 2019 | ($6.78M) | Dec 9, 2020 |
| FY2019 | Sep 30, 2018 | ($5.13M) | Dec 20, 2019 |
| FY2017 | Sep 30, 2017 | ($944.4K) | Apr 16, 2018 |
| FY2017 | Jun 30, 2017 | ($1.95M) | Apr 16, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($4.23M) | Dec 17, 2025 |
| FY2025 | Sep 30, 2024 | ($11.89M) | Dec 17, 2025 |
| FY2024 | Sep 30, 2023 | ($11.96M) | Dec 17, 2024 |
| FY2023 | Sep 30, 2022 | ($10.03M) | Dec 15, 2023 |
| FY2022 | Sep 30, 2021 | ($10.22M) | Dec 22, 2022 |
| FY2021 | Sep 30, 2020 | ($4.90M) | May 31, 2022 |
| FY2020 | Sep 30, 2019 | ($5.81M) | Dec 9, 2020 |
| FY2019 | Sep 30, 2018 | ($3.39M) | Dec 20, 2019 |
| FY2016 | Dec 31, 2016 | ($32.6K) | Apr 17, 2017 |
| FY2016 | Dec 31, 2015 | ($30.9K) | Apr 17, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $4.98M | Dec 17, 2025 |
| FY2025 | Sep 30, 2024 | $5.07M | Dec 17, 2025 |
| FY2024 | Sep 30, 2023 | $6.94M | Dec 17, 2024 |
| FY2023 | Sep 30, 2022 | $4.93M | Dec 15, 2023 |
| FY2022 | Sep 30, 2021 | $3.93M | Dec 22, 2022 |
| FY2021 | Sep 30, 2020 | $2.08M | May 31, 2022 |
| FY2020 | Sep 30, 2019 | $1.53M | Dec 9, 2020 |
| FY2019 | Sep 30, 2018 | $715.1K | Dec 20, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $7.38M | Dec 17, 2025 |
| FY2025 | Sep 30, 2024 | $7.90M | Dec 17, 2025 |
| FY2024 | Sep 30, 2023 | $6.93M | Dec 17, 2024 |
| FY2023 | Sep 30, 2022 | $6.98M | Dec 15, 2023 |
| FY2022 | Sep 30, 2021 | $6.26M | Dec 22, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($2.84M) | Dec 17, 2025 |
| FY2025 | Sep 30, 2024 | ($11.01M) | Dec 17, 2025 |
| FY2024 | Sep 30, 2023 | ($12.89M) | Dec 17, 2024 |
| FY2023 | Sep 30, 2022 | ($7.52M) | Dec 15, 2023 |
| FY2022 | Sep 30, 2021 | ($8.60M) | Dec 22, 2022 |
| FY2021 | Sep 30, 2020 | ($3.43M) | May 31, 2022 |
| FY2020 | Sep 30, 2019 | ($5.40M) | Dec 9, 2020 |
| FY2019 | Sep 30, 2018 | ($2.23M) | Dec 20, 2019 |
| FY2012 | Dec 31, 2012 | ($13.7K) | Apr 11, 2013 |
| FY2012 | Dec 31, 2011 | ($27.4K) | Apr 11, 2013 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $81.7K | Dec 17, 2025 |
| FY2025 | Sep 30, 2024 | $120.2K | Dec 17, 2025 |
| FY2024 | Sep 30, 2023 | $384.1K | Dec 17, 2024 |
| FY2023 | Sep 30, 2022 | $275.2K | Dec 15, 2023 |
| FY2022 | Sep 30, 2021 | $67.1K | Dec 22, 2022 |
| FY2021 | Sep 30, 2020 | $122.4K | May 31, 2022 |
| FY2020 | Sep 30, 2019 | $58.4K | Dec 9, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $10.79M | Dec 17, 2025 |
| FY2025 | Sep 30, 2024 | $5.37M | Dec 17, 2025 |
| FY2024 | Sep 30, 2023 | $8.10M | Dec 17, 2024 |
| FY2023 | Sep 30, 2022 | $12.82M | Dec 15, 2023 |
| FY2022 | Sep 30, 2021 | $7.94M | Dec 22, 2022 |
| FY2021 | Sep 30, 2020 | $4.76M | May 31, 2022 |
| FY2020 | Sep 30, 2019 | $532.6K | Dec 9, 2020 |
| FY2019 | Sep 30, 2018 | $218.7K | Dec 20, 2019 |
| FY2017 | Dec 31, 2017 | $250.0K | Apr 16, 2018 |
| FY2017 | Dec 31, 2016 | $756.9K | Apr 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $3.71M | Dec 17, 2025 |
| FY2025 | Sep 30, 2024 | $4.55M | Dec 17, 2025 |
| FY2024 | Sep 30, 2023 | $1.85M | Dec 17, 2024 |
| FY2023 | Sep 30, 2022 | $3.22M | Dec 15, 2023 |
| FY2022 | Sep 30, 2021 | $1.38M | Dec 22, 2022 |
| FY2021 | Sep 30, 2020 | $2.69M | May 31, 2022 |
| FY2020 | Sep 30, 2019 | $1.77M | Dec 9, 2020 |
| FY2019 | Sep 30, 2018 | $4.61M | Dec 20, 2019 |
| FY2017 | Dec 31, 2017 | $5.29M | Apr 16, 2018 |
| FY2017 | Dec 31, 2016 | $1.02M | Apr 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $7.07M | Dec 17, 2025 |
| FY2025 | Sep 30, 2024 | $822.0K | Dec 17, 2025 |
| FY2025 | Sep 30, 2023 | $6.25M | Dec 17, 2025 |
| FY2024 | Sep 30, 2022 | $9.60M | Dec 17, 2024 |
| FY2023 | Sep 30, 2021 | $6.55M | Dec 15, 2023 |
| FY2022 | Sep 30, 2020 | $2.07M | Dec 22, 2022 |
| FY2021 | Sep 30, 2019 | ($1.24M) | May 31, 2022 |
| FY2020 | Sep 30, 2018 | ($4.40M) | Dec 9, 2020 |
| FY2019 | Dec 31, 2017 | ($5.04M) | Dec 20, 2019 |
| FY2017 | Dec 31, 2016 | ($266.2K) | Apr 16, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($78.61M) | Dec 17, 2025 |
| FY2025 | Sep 30, 2024 | ($75.00M) | Dec 17, 2025 |
| FY2024 | Sep 30, 2023 | ($62.69M) | Dec 17, 2024 |
| FY2023 | Sep 30, 2022 | ($50.83M) | Dec 15, 2023 |
| FY2022 | Sep 30, 2021 | ($40.83M) | Dec 22, 2022 |
| FY2021 | Sep 30, 2020 | ($30.88M) | May 31, 2022 |
| FY2020 | Sep 30, 2019 | ($17.24M) | Dec 9, 2020 |
| FY2019 | Sep 30, 2018 | ($10.46M) | Dec 20, 2019 |
| FY2017 | Dec 31, 2017 | ($5.32M) | Apr 16, 2018 |
| FY2017 | Dec 31, 2016 | ($266.4K) | Apr 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $6.57M | Dec 17, 2025 |
| FY2025 | Sep 30, 2024 | $1.46M | Dec 17, 2025 |
| FY2024 | Sep 30, 2023 | $5.32M | Dec 17, 2024 |
| FY2023 | Sep 30, 2022 | $8.16M | Dec 15, 2023 |
| FY2022 | Sep 30, 2021 | $6.90M | Dec 22, 2022 |
| FY2021 | Sep 30, 2020 | $4.04M | May 31, 2022 |
| FY2021 | Sep 30, 2019 | $260.7K | Dec 15, 2021 |
| FY2020 | Sep 30, 2018 | $13.3K | Dec 9, 2020 |
| FY2019 | Dec 31, 2017 | $26.5K | Dec 20, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Dec 17, 2025 |
| FY2025 | Sep 30, 2024 | 0 | Dec 17, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Dec 17, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Dec 15, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Dec 22, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Dec 17, 2025 |
| FY2025 | Sep 30, 2024 | 0 | Dec 17, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Dec 17, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Dec 15, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Dec 22, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 50.01M | Dec 17, 2025 |
| FY2025 | Sep 30, 2024 | 30.82M | Dec 17, 2025 |
| FY2024 | Sep 30, 2023 | 23.93M | Dec 17, 2024 |
| FY2023 | Sep 30, 2022 | 16.22M | Dec 15, 2023 |
| FY2022 | Sep 30, 2021 | 12.01M | Dec 22, 2022 |
| FY2021 | Sep 30, 2020 | 7.39M | May 31, 2022 |
| FY2020 | Sep 30, 2019 | 13.49M | Dec 9, 2020 |
| FY2019 | Sep 30, 2018 | 9.66M | Dec 20, 2019 |
| FY2017 | Dec 31, 2017 | 7.86M | Apr 16, 2018 |
| FY2017 | Dec 31, 2016 | 5.22M | Apr 16, 2018 |